Home Featured Page 265

Featured

Latest

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit Model of Consciousness

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

PT246 – Amber and Marcus Capone of VETS – Foundational Healing...

MYND Life Sciences announces Depression Biomarker Diagnostic Program

Horizons ETFs Announces Methodology Update for the North American Psychedelics Index

Filament Health Partners with TrPR Psychedelic Research Program at UCSF to...

Can Psychedelics Help Heal Moral Injury?

Psychedelic Bulletin: COMPASS Pathways’ 4th Patent; MagicMed to Be Acquired; MindMed...

MindMed announces shareholder Meeting Results

PTSF61 – Archetypal Astrology and the Inner Healer, with Renn Butler

MYND Life Sciences Inc. Establishes Scientific Advisory Board

The Psilocybin vs. Escitalopram Trial – Part 1

EDITOR PICKS

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit...

Quarterly Psychedelics Briefing: Q2 2026

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit Model of Consciousness

Quarterly Psychedelics Briefing: Q2 2026

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

PT246 – Amber and Marcus Capone of VETS – Foundational Healing...

MYND Life Sciences announces Depression Biomarker Diagnostic Program

Horizons ETFs Announces Methodology Update for the North American Psychedelics Index

Filament Health Partners with TrPR Psychedelic Research Program at UCSF to...

Can Psychedelics Help Heal Moral Injury?

Psychedelic Bulletin: COMPASS Pathways’ 4th Patent; MagicMed to Be Acquired; MindMed...

MindMed announces shareholder Meeting Results

PTSF61 – Archetypal Astrology and the Inner Healer, with Renn Butler

MYND Life Sciences Inc. Establishes Scientific Advisory Board

The Psilocybin vs. Escitalopram Trial – Part 1

EDITOR PICKS

Psychedelics Today at the Aspen Psychedelic Symposium

The Framework Gap in Psychedelic Practice: An Introduction to the 8-Circuit...

Quarterly Psychedelics Briefing: Q2 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY